Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity
Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today initiation of Phase 1b clinical study which is designed to provide proof-of-concept weight loss results, along with safety and tolerability, using an optimized formulation of the drug candidate XEN-101, in obese adults. The trial is expected to have top line results by the end of the year. The Phase 1b study is a double blinded, randomized, placebo controlled, parallel group design testing multiple doses of Xen-101 vs. placebo over 4-week period in 32 adults with BMI between 30 and 45 kg/m2. The study is being conducted in Australia and safety, tolerability, and total body weight change at the 4-week endpoint will be the primary objectives. Read more >>